Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL986067 | 0.88 | KMT2A (0.48) | KMT2AALDH1A1LMNACYP3A4CYP2D6 | |
| SCHEMBL6176608 | 0.86 | KMT2A (0.47) | KMT2AALDH1A1LMNACYP3A4CYP2D6 | |
| SCHEMBL1030015 | 0.86 | ALDH1A1 (0.53) | KMT2AALDH1A1LMNACYP3A4CYP2D6 | |
| SCHEMBL10827238 | 0.86 | KMT2A (0.47) | KMT2AALDH1A1LMNACYP3A4CYP2D6 | |
| SCHEMBL7815599 | 0.84 | KMT2A (0.50) | KMT2AALDH1A1LMNACYP3A4CYP2D6 | |
| SCHEMBL113808 | 0.84 | CYP2D6 (0.46) | KMT2AALDH1A1LMNACYP3A4CYP2D6 | |
| SCHEMBL28657119 | 0.82 | CA1 (0.47) | KMT2ATSHRL3MBTL1 | |
| SCHEMBL28623093 | 0.81 | KMT2A (0.47) | KMT2AALDH1A1LMNACYP3A4HCAR2 | |
| SCHEMBL11386291 | 0.81 | KMT2A (0.47) | KMT2AALDH1A1LMNACYP3A4CYP2D6 | |
| SCHEMBL396502 | 0.80 | HCAR2 (0.42) | KMT2AALDH1A1LMNACYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 404 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012131077-A1 | SOMATOSTATIN MIMETICS | NATIONAL UNIVERSITY OF IRELAND, GALWAY (IE) | 2012-10-04 | — | — | WO | claimed |
| EP-3125943-B1 | PHOSPHATE BASED LINKERS FOR INTRACELLULAR DELIVERY OF DRUG CONJUGATES | MERCK SHARP & DOHME LLC (US) | 2026-04-22 | — | — | EP | disclosed |
| WO-2024151519-A2 | PPARG MODULATORS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATIN, INCORPORATED (US) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024147060-A1 | NOVEL IONIZABLE LIPID COMPOUNDS FOR NUCLEIC ACID DELIVERY | CELON PHARMA S.A. (PL) | 2024-07-11 | — | — | WO | disclosed |
| WO-2024133853-A1 | BIS-ESTER AND AMIDE CATIONIC LIPIDS | SANOFI (FR) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024123978-A1 | IONIZABLE LIPIDS WITH MALONATE TAILS | MODERNATX, INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024112854-A1 | INHIBITORS OF RIPK2 AND MEDICAL USES THEREOF | ODYSSEY THERAPEUTICS, INC. (US) | 2024-05-30 | — | — | WO | disclosed |
| EP-4370503-A1 | ESTERS OF A RETINOID AND BAKUCHIOL AND PREPARATIONS THEREOF | Conagen Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| WO-2024097948-A1 | DEGRADERS OF MDM2 AND USES THEREOF | ROIVANT DISCOVERY, INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| WO-2024097746-A1 | ALKENE CYCLOPROPANATION WITH NICKEL CATALYST ENHANCER AND IMPROVED REARRANGEMENT REACTION | CONAGEN INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| WO-2008063300-A2 | BORONIC ACIDS AND ESTERS AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008048714-A2 | BIRADICAL POLARIZING AGENTS FOR DYNAMIC NUCLEAR POLARIZATION | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2008-04-24 | — | — | WO | disclosed |
| WO-2008028057-A2 | SHIKIMIC ACID-DERIVED COMPOUNDS FOR INHIBITION AND DETECTION OF AURORA A-ASSOCIATED TUMORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2008-03-06 | — | — | WO | disclosed |
| US-20070167506-A1 | SUBSTITUTED IMIDAZOLES | PFIZER INC. (US) | 2007-07-19 | — | — | US | disclosed |
| EP-1753713-A2 | SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF | The President and Fellows of Harvard College (US) | 2007-02-21 | — | — | EP | disclosed |
| WO-2007013965-A2 | SYNTHESIS OF SCABRONINES AND ANALOGUES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2007-02-01 | — | — | WO | disclosed |
| WO-2005112945-A2 | SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF | THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2005-12-01 | — | — | WO | disclosed |
| EP-1005338-A4 | SUBSTITUTED AURONE DERIVATIVES | PHYTERA INC (US) | 2001-11-07 | — | — | EP | disclosed |
| EP-1005338-A1 | SUBSTITUTED AURONE DERIVATIVES | PHYTERA, INC. (US) | 2000-06-07 | — | — | EP | disclosed |
| WO-1999004789-A1 | SUBSTITUTED AURONE DERIVATIVES | PHYTERA, INC. (US) | 1999-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167506-A1 | SUBSTITUTED IMIDAZOLES | ABL1, TYR, CYP3A4 | KMT2A 945/4885ALDH1A1 617/4885LMNA 3030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.